Product Revenue up 25% from Fiscal 2023 Q2
Company to Host Webcast February 23rd at 11:00 a.m. ET
Transphorm, Inc. (NASDAQ: TGAN)—a pioneer in and global supplier of high-reliability, high-performance gallium nitride (GaN) power conversion products, announced today financial results for its 2023 fiscal third quarter ended December 31, 2022.
Fiscal 2023 Third Quarter and Recent Highlights
(All comparisons are to the third quarter of fiscal 2022, unless otherwise noted.)
- Revenue of $4.5 million, compared to revenue of $3.7 million in the prior quarter, and $4.6 million in fiscal 2022. Product revenue was up 25% on a sequential basis and 9% compared to the same period in fiscal 2022.
- Increased total design-ins for power adapters and fast chargers to over 80 (with over 25 in production) and total design-ins for higher power (300 Watt – 4 Kilowatt) to over 55 (with over 25 in production).
- Robust 5-year pipeline opportunity now stands at over $400 million.
- Shipping production quantities of Transphorm SuperGaN Technology used in HPi (“HP”) power adapter (as revealed by a recent product teardown), solidifying the company’s GaN-FET technology in the low and mid-power adapter space.
- Secured and shipped a new production order for 100 thousand units for another world-wide top 5 laptop manufacturer.
- New >2 kW UPS production win with a global leader in energy, continuing Transphorm leadership in high-power GaN.
- The Company’s products have exceeded 100 billion hours of field operating reliability including in both low-power and high-power applications. We believe this is one of the industry’s best and only reported broad power spectrum reliability rating for GaN power.
- Announced the availability of a new 240W Power Adapter Reference Design, which brings industry-standard Thru-Hole Packaging delivering power density advantages at low cost to power supplies.
- Completed submission for a $15 million Navy program, which, if awarded, will expand MOCVD manufacturing capacity and capability to increase the Company’s RF Epiwafer sales (TGAN’s 2nd business vertical).
Transphorm President, COO, and Co-founder, Primit Parikh, commented, “We grew revenue 22% sequentially and remain well-positioned to achieve our long-term operating goals. Our business momentum is exemplified by another strong quarter of design wins as we aggressively pursued and won numerous additional designs in both high-power and low-power markets, including world-wide tier-1 leaders like HP, which represents a significant milestone and the culmination of our intense dedication to quality and reliability, with ease of use and top performance. We look forward to building on our success in this segment of the adapter market, while further growing our leadership in high-power which comprised more than 70% of our revenue in the quarter.”
Dr. Parikh added, “While we still face near term macro-headwinds, we remain well-positioned to translate the above momentum to business growth in fiscal 2024. We also made solid progress on our plans to ramp up additional capacity over the coming year, in order to be prepared and ready to meet the significant demand that lies ahead.”
“This quarter saw solid execution and higher than expected revenues, with our product revenues being driven by strong traction in the Higher Power space. As we enter calendar year 2023, the Company is well positioned and remains keenly focused on achieving continued short-term momentum and long-term growth, driven by a robust pipeline,” stated Cameron McAulay, Chief Financial Officer.
Fiscal 2023 Third Quarter Financial Results
Revenue for the third quarter of fiscal 2023 was $4.5 million, compared to $3.7 million in the prior quarter and $4.6 million for the third quarter of fiscal 2022. Product revenue reflected yet another strong quarter from ramping shipments of GaN products for a broad range of power conversion applications, with a 25% increase over the prior quarter and a 9% increase from the third quarter of fiscal 2022.
Operating expenses on a GAAP basis were $7.2 million in the third quarter of fiscal 2023, compared to $5.9 million in the prior quarter and $5.4 million in the third quarter of fiscal 2022. Third quarter of fiscal 2023 operating expenses consisted of R&D expenses of $2.3 million and SG&A expenses of $4.9 million. On a non-GAAP basis, operating expenses in the third quarter of fiscal 2023 were $5.9 million, compared with non-GAAP operating expenses of $5.1 million in the prior quarter and $4.4 million in the third quarter of fiscal 2022.
GAAP net loss for the third quarter of fiscal 2023 was ($10.5) million, or ($0.18) per share, compared to GAAP net loss of ($6.0) million, or ($0.10) per share, in the prior quarter, and GAAP net loss of ($4.2) million, or ($0.08) per share, in the third quarter of fiscal 2022. On a non-GAAP basis, net loss for the third quarter of fiscal 2023 was ($9.1) million, or ($0.16) per share, compared to non-GAAP net loss of ($5.1) million, or ($0.09) per share, in the prior quarter, and non-GAAP net loss of ($4.3) million, or ($0.09) per share, in the third quarter of fiscal 2022. These numbers for the third quarter included a one time write-off of $2.8 million, or ($0.05) per share for epiwafer inventory largely resulting from the process of bringing up our Japan epi reactors over the last several quarters.
Cash, cash equivalents and restricted cash as of December 31, 2022, were $23.6 million.
Conference Call and Webcast Information
Event: |
Transphorm Fiscal 2023 Third Quarter Financial Results |
Date: |
Thursday, February 23, 2023 |
Time: |
11:00 a.m. Eastern Time |
Registration: |
https://register.vevent.com/register/BI851a7746d2294d99978db9598035906d |
Investors and analysts will receive a unique dial-in number and PIN number, once registered.
A replay and the supporting presentation materials will be available on the day of the conference call and for approximately 90 days on the Investor Relations section of the Company’s website. Additionally, an audio replay of the conference call will be available after the conclusion of the call and through March 2, 2023.
About Transphorm
Transphorm, Inc., a global leader in the GaN revolution, designs and manufactures high performance and high reliability GaN semiconductors for high voltage power conversion applications. Having one of the largest Power GaN IP portfolios of more than 1,000 owned or licensed patents, Transphorm produces the industry’s first JEDEC and AEC-Q101 qualified high voltage GaN semiconductor devices. The Company’s vertically integrated device business model allows for innovation at every development stage: design, fabrication, device, and application support. Transphorm’s innovations are moving power electronics beyond the limitations of silicon to achieve over 99% efficiency, 40% more power density and 20% lower system cost. Transphorm is headquartered in Goleta, California and has manufacturing operations in Goleta and Aizu, Japan. For more information, please visit www.transphormusa.com. Follow us on Twitter @transphormusa and WeChat @ Transphorm GaN.
Non-GAAP Financial Measures
This press release includes and makes reference to certain non-GAAP financial measures. The presentation of this financial information is not intended to be considered in isolation or as a substitute for the financial information prepared and presented in accordance with GAAP.
Transphorm believes that the presentation of non-GAAP financial measures provides important supplemental information to management and investors regarding financial and business trends relating to the Company’s financial condition and results of operations. Transphorm believes that these non-GAAP financial measures provide additional insight into Transphorm’s ongoing performance and core operational activities and has chosen to provide these measures for more consistent and meaningful comparison between periods. These measures should only be used to evaluate Transphorm’s results of operations in conjunction with the corresponding GAAP measures. The non-GAAP results exclude the effect of stock-based compensation, depreciation, amortization, change in fair value of promissory note and other income in joint venture.
A reconciliation between GAAP and non-GAAP financial results is provided in the financial statements portion of this press release.
Forward-Looking Statements
This press release contains forward-looking statements (including within the meaning of Section 21E of the United States Securities Exchange Act of 1934, as amended, and Section 27A of the United States Securities Act of 1933, as amended) concerning the Company’s positioning to achieve long-term operating goals, the Company’s ability to expand its manufacturing capacity and meet anticipated demand, industry acceptance of GaN technology, and the Company’s pipeline and future anticipated growth. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as “may,” “will,” “should,” “would,” “expect,” “plan,” “believe,” “intend,” “look forward,” and other similar expressions among others. Statements that are not historical facts are forward-looking statements. Forward-looking statements are based on current beliefs and assumptions that are subject to risks and uncertainties and are not guarantees of future performance. Actual results could differ materially from those contained in any forward-looking statement as a result of various factors, including, without limitation: risks related to Transphorm’s operations, such as additional financing requirements and access to capital; competition; the ability of Transphorm to protect its intellectual property rights; and other risks set forth in the Company’s filings with the Securities and Exchange Commission. Except as required by applicable law, the Company undertakes no obligation to revise or update any forward-looking statement, or to make any other forward-looking statements, whether as a result of new information, future events or otherwise.
Transphorm, Inc. Condensed Consolidated Balance Sheets (in thousands) |
|||||||
|
December 31, 2022
|
|
March 31, 2022
|
||||
Assets |
|
|
|
||||
Current assets: |
|
|
|
||||
Cash and cash equivalents |
$ |
23,149 |
|
|
$ |
33,435 |
|
Restricted cash |
|
500 |
|
|
|
500 |
|
Accounts receivable |
|
3,704 |
|
|
|
2,558 |
|
Inventory |
|
7,476 |
|
|
|
6,330 |
|
Prepaid expenses and other current assets |
|
1,570 |
|
|
|
1,971 |
|
Total current assets |
|
36,399 |
|
|
|
44,794 |
|
Property and equipment, net |
|
5,367 |
|
|
|
1,649 |
|
Operating lease right-of-use assets |
|
3,173 |
|
|
|
— |
|
Goodwill |
|
1,097 |
|
|
|
1,180 |
|
Intangible assets, net |
|
395 |
|
|
|
617 |
|
Investment in joint venture |
|
647 |
|
|
|
143 |
|
Other assets |
|
2,167 |
|
|
|
263 |
|
Total assets |
$ |
49,245 |
|
|
$ |
48,646 |
|
|
|
|
|
||||
Liabilities and stockholders’ equity |
|
|
|
||||
Current liabilities: |
|
|
|
||||
Accounts payable and accrued expenses |
$ |
4,016 |
|
|
$ |
3,588 |
|
Deferred revenue |
|
— |
|
|
|
346 |
|
Accrued interest |
|
184 |
|
|
|
180 |
|
Accrued payroll and benefits |
|
1,657 |
|
|
|
1,171 |
|
Operating lease liabilities |
|
536 |
|
|
|
— |
|
Revolving credit facility |
|
12,000 |
|
|
|
— |
|
Total current liabilities |
|
18,393 |
|
|
|
5,285 |
|
Revolving credit facility, net of current portion |
|
— |
|
|
|
12,000 |
|
Operating lease liabilities, net of current portion |
|
2,670 |
|
|
|
— |
|
Total liabilities |
|
21,063 |
|
|
|
17,285 |
|
Commitments and contingencies |
|
|
|
||||
Stockholders’ equity: |
|
|
|
||||
Common stock |
|
6 |
|
|
|
5 |
|
Additional paid-in capital |
|
229,954 |
|
|
|
211,190 |
|
Accumulated deficit |
|
(200,446 |
) |
|
|
(178,638 |
) |
Accumulated other comprehensive loss |
|
(1,332 |
) |
|
|
(1,196 |
) |
Total Stockholders’ equity |
|
28,182 |
|
|
|
31,361 |
|
Total liabilities and stockholders’ equity |
$ |
49,245 |
|
|
$ |
48,646 |
|
Transphorm, Inc. Condensed Consolidated Statements of Operations (unaudited) (in thousands except share and per share data) |
|||||||||||||||||||
|
Three Months Ended |
|
Nine Months Ended |
||||||||||||||||
|
December 31, 2022 |
|
September 30, 2022 |
|
December 31, 2021 |
|
December 31, 2022 |
|
December 31, 2021 |
||||||||||
Revenue, net |
$ |
4,493 |
|
|
$ |
3,670 |
|
|
$ |
4,604 |
|
|
$ |
13,319 |
|
|
$ |
19,123 |
|
Cost of goods sold |
|
7,162 |
|
|
|
3,232 |
|
|
|
3,935 |
|
|
|
14,444 |
|
|
|
8,741 |
|
Gross (loss) profit |
|
(2,669 |
) |
|
|
438 |
|
|
|
669 |
|
|
|
(1,125 |
) |
|
|
10,382 |
|
Operating expenses: |
|
|
|
|
|
|
|
|
|
||||||||||
Research and development |
|
2,325 |
|
|
|
1,830 |
|
|
|
1,609 |
|
|
|
5,895 |
|
|
|
5,023 |
|
Sales and marketing |
|
1,447 |
|
|
|
1,066 |
|
|
|
976 |
|
|
|
3,596 |
|
|
|
2,488 |
|
General and administrative |
|
3,457 |
|
|
|
3,044 |
|
|
|
2,852 |
|
|
|
9,818 |
|
|
|
8,309 |
|
Total operating expenses |
|
7,229 |
|
|
|
5,940 |
|
|
|
5,437 |
|
|
|
19,309 |
|
|
|
15,820 |
|
Loss from operations |
|
(9,898 |
) |
|
|
(5,502 |
) |
|
|
(4,768 |
) |
|
|
(20,434 |
) |
|
|
(5,438 |
) |
Interest expense |
|
184 |
|
|
|
184 |
|
|
|
187 |
|
|
|
550 |
|
|
|
611 |
|
Loss in joint venture |
|
799 |
|
|
|
684 |
|
|
|
712 |
|
|
|
2,065 |
|
|
|
3,294 |
|
Changes in fair value of promissory note |
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
(605 |
) |
Other income, net |
|
(421 |
) |
|
|
(375 |
) |
|
|
(1,503 |
) |
|
|
(1,241 |
) |
|
|
(3,502 |
) |
Loss before tax expense |
|
(10,460 |
) |
|
|
(5,995 |
) |
|
|
(4,164 |
) |
|
|
(21,808 |
) |
|
|
(5,236 |
) |
Tax expense |
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
Net loss |
$ |
(10,460 |
) |
|
$ |
(5,995 |
) |
|
$ |
(4,164 |
) |
|
$ |
(21,808 |
) |
|
$ |
(5,236 |
) |
Net loss per share - basic and diluted |
$ |
(0.18 |
) |
|
$ |
(0.10 |
) |
|
$ |
(0.08 |
) |
|
$ |
(0.38 |
) |
|
$ |
(0.12 |
) |
Weighted average common shares outstanding - basic and diluted |
|
56,739,450 |
|
|
|
56,619,662 |
|
|
|
49,147,630 |
|
|
|
55,926,828 |
|
|
|
43,671,321 |
|
Transphorm, Inc. Reconciliation of GAAP and Non-GAAP Financial Information (unaudited) (in thousands except share and per share data) |
|||||||||||||||||||
|
Three Months Ended |
|
Nine Months Ended |
||||||||||||||||
|
December 31, 2022 |
|
September 30, 2022 |
|
December 31, 2021 |
|
December 31, 2022 |
|
December 31, 2021 |
||||||||||
GAAP net loss |
$ |
(10,460 |
) |
|
$ |
(5,995 |
) |
|
$ |
(4,164 |
) |
|
$ |
(21,808 |
) |
|
$ |
(5,236 |
) |
Adjustments: |
|
|
|
|
|
|
|
|
|
||||||||||
Stock-based compensation |
|
1,123 |
|
|
|
636 |
|
|
|
848 |
|
|
|
2,341 |
|
|
|
1,856 |
|
Depreciation |
|
180 |
|
|
|
165 |
|
|
|
142 |
|
|
|
497 |
|
|
|
399 |
|
Amortization |
|
74 |
|
|
|
74 |
|
|
|
74 |
|
|
|
222 |
|
|
|
222 |
|
Changes in fair value of promissory note |
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
(605 |
) |
Other income |
|
— |
|
|
|
— |
|
|
|
(1,222 |
) |
|
|
— |
|
|
|
(2,677 |
) |
Total adjustments to GAAP net loss |
|
1,377 |
|
|
|
875 |
|
|
|
(158 |
) |
|
|
3,060 |
|
|
|
(805 |
) |
Non-GAAP net loss |
$ |
(9,083 |
) |
|
$ |
(5,120 |
) |
|
$ |
(4,322 |
) |
|
$ |
(18,748 |
) |
|
$ |
(6,041 |
) |
GAAP net loss per share - basic and diluted |
$ |
(0.18 |
) |
|
$ |
(0.10 |
) |
|
$ |
(0.08 |
) |
|
$ |
(0.38 |
) |
|
$ |
(0.12 |
) |
Adjustment |
|
0.01 |
|
|
|
0.01 |
|
|
|
(0.01 |
) |
|
|
0.04 |
|
|
|
(0.02 |
) |
Non-GAAP net loss per share - basic and diluted |
$ |
(0.16 |
) |
|
$ |
(0.09 |
) |
|
$ |
(0.09 |
) |
|
$ |
(0.33 |
) |
|
$ |
(0.14 |
) |
|
|
|
|
|
|
|
|
|
|
||||||||||
|
Three Months Ended |
|
Nine Months Ended |
||||||||||||||||
|
December 31, 2022 |
|
September 30, 2022 |
|
December 31, 2021 |
|
December 31, 2022 |
|
December 31, 2021 |
||||||||||
GAAP operating expenses |
$ |
7,229 |
|
$ |
5,940 |
|
$ |
5,437 |
|
$ |
19,309 |
|
$ |
15,820 |
|||||
Adjustments: |
|
|
|
|
|
|
|
|
|
||||||||||
Stock-based compensation |
|
1,035 |
|
|
583 |
|
|
796 |
|
|
2,161 |
|
|
1,738 |
|||||
Depreciation |
|
180 |
|
|
165 |
|
|
142 |
|
|
497 |
|
|
399 |
|||||
Amortization |
|
74 |
|
|
74 |
|
|
74 |
|
|
222 |
|
|
222 |
|||||
Total adjustments to GAAP operating expenses |
|
1,289 |
|
|
822 |
|
|
1,012 |
|
|
2,880 |
|
|
2,359 |
|||||
Non-GAAP operating expenses |
$ |
5,940 |
|
$ |
5,118 |
|
$ |
4,425 |
|
$ |
16,429 |
|
$ |
13,461 |
|||||
Transphorm, Inc. Condensed Consolidated Statements of Cash Flows (unaudited) (in thousands) |
|||||||
|
Nine Months Ended December 31, |
||||||
|
|
2022 |
|
|
|
2021 |
|
Cash flows from operating activities: |
|
|
|
||||
Net loss |
$ |
(21,808 |
) |
|
$ |
(5,236 |
) |
Adjustments to reconcile net loss to net cash used in operating activities: |
|
|
|
||||
Inventory write-off |
|
2,810 |
|
|
|
202 |
|
Depreciation and amortization |
|
719 |
|
|
|
621 |
|
Amortization of right-of-use assets |
|
425 |
|
|
|
— |
|
Perpetual licensing revenue from a related party |
|
— |
|
|
|
(8,000 |
) |
Stock-based compensation |
|
2,342 |
|
|
|
1,856 |
|
Interest cost |
|
4 |
|
|
|
295 |
|
Gain on promissory note conversion |
|
— |
|
|
|
(1,222 |
) |
Gain on sale of equipment |
|
(110 |
) |
|
|
— |
|
Loss in joint venture |
|
2,065 |
|
|
|
1,839 |
|
Changes in fair value of derivative instruments |
|
75 |
|
|
|
— |
|
Changes in fair value of promissory note |
|
— |
|
|
|
(605 |
) |
Changes in operating assets and liabilities: |
|
|
|
||||
Accounts receivable |
|
(1,221 |
) |
|
|
(871 |
) |
Inventory |
|
(3,956 |
) |
|
|
(3,935 |
) |
Prepaid expenses and other current assets |
|
401 |
|
|
|
204 |
|
Other assets |
|
(504 |
) |
|
|
(8 |
) |
Accounts payable and accrued expenses |
|
428 |
|
|
|
1,359 |
|
Deferred revenue |
|
(346 |
) |
|
|
(238 |
) |
Accrued payroll and benefits |
|
486 |
|
|
|
(171 |
) |
Operating lease liabilities |
|
(392 |
) |
|
|
— |
|
Net cash used in operating activities |
|
(18,582 |
) |
|
|
(13,910 |
) |
Cash flows from investing activities: |
|
|
|
||||
Advances and purchases of property and equipment |
|
(5,633 |
) |
|
|
(690 |
) |
Proceeds from sale of equipment |
|
110 |
|
|
|
— |
|
Investment in joint venture |
|
(2,569 |
) |
|
|
(3,765 |
) |
Net cash used in investing activities |
|
(8,092 |
) |
|
|
(4,455 |
) |
Cash flows from financing activities: |
|
|
|
||||
Proceeds from stock option exercise |
|
709 |
|
|
|
134 |
|
Proceeds from issuance of common stock |
|
16,000 |
|
|
|
49,773 |
|
Cost associated with issuance of common stock |
|
(280 |
) |
|
|
— |
|
Payment for taxes related to net share settlement of restricted stock units |
|
(6 |
) |
|
|
||
Net cash provided by financing activities |
|
16,423 |
|
|
|
49,907 |
|
Effect of foreign exchange rate changes on cash, cash equivalents and restricted cash |
|
(35 |
) |
|
|
(75 |
) |
Net (decrease) increase in cash, cash equivalents and restricted cash |
|
(10,286 |
) |
|
|
31,467 |
|
Cash and cash equivalents and restricted cash at beginning of period |
|
33,935 |
|
|
|
9,500 |
|
Cash and cash equivalents at end of period |
|
23,149 |
|
|
|
40,467 |
|
Restricted cash at end of period |
|
500 |
|
|
|
500 |
|
Cash and cash equivalents and restricted cash at end of period |
$ |
23,649 |
|
|
$ |
40,967 |
|
View source version on businesswire.com: https://www.businesswire.com/news/home/20230222005346/en/
Contacts
Investor Contacts:
David Hanover or Jack Perkins
KCSA Strategic Communications
transphorm@kcsa.com
Company Contact:
Cameron McAulay
Chief Financial Officer
1-805-456-1300 ext. 140
cmcaulay@transphormusa.com
